This summary is generated by an algorithm. If you find any mistakes, let us know.

Biotechnology Health Care Medical North America

Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics

– Presage Biosciences closed a $13m financing and commenced new research collaborations with Merck and Maverick Therapeutics.
– The financing includes $7m raised from new investors, including the LabCorp Venture Fund, Bristol Myers Squibb, and InHarv Partners Ltd.
– An additional $6m convertible note from Takeda Ventures will convert to equity.
– The proceeds from this financing will support expansion of Presage’s existing network of clinical sites in the U.S. and Australia, as well as development of next-generation CIVO microdose injection devices designed to access a wider spectrum of cancers.
– Presage has pioneered a new approach to early evaluation of investigational cancer drugs and combinations in clinical trials with a technology that enables detailed assessment of multiple drugs simultaneously in patients with solid tumors.

Crunchbase icon

Content report

The following text will be sent to our editors: